Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Oxford, UK : Blackwell Publishing Ltd
    Journal of interventional cardiology 1 (1988), S. 0 
    ISSN: 1540-8183
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: A new angiographic method of determining the anatomy of a patent ductus arteriosus (PDA) preparatory to its surgical or nonsurgical closure has been developed and compared to conventional angiographic techniques in 17 patients using a new low pressure balloon catheter (Edwards). The balloon, 5 cm long, is filled with contrast material and expanded to any diameter up to 20 mm. It may be passed into the ductus from either the arterial (14 patients) or venous (3 patients) side. The balloon is expanded by radiopaque material adjacent to the aortic orifice of the PDA and advanced (or pulled) through the ductus. Deformation of the balloon identified the length and caliber of the PDA providing virtually identical estimates thereof in all 17 patients when compared to conventional angiography. On the other hand, visualization of the PDA was good in only 41 (62%) or tolerable in 14 (21%) of 66 conventionally studied patients. (J In-terven Cardiol 1988:1:2)
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1432-1440
    Keywords: Intravenous nitroglycerin ; Acute myocardial infarction ; Untreated control group ; Late intervention ; CK and CK-MB infarct-size ; Intravenöses Nitroglycerin ; akuter Herzinfarkt ; nicht behandelte Kontrollgruppe ; späte Intervention ; CK- und CK-MB Infarktgröße
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Bei 38 Patienten mit frischem Herzinfarkt wurde die Wirkung von Nitroglycerin auf die Infarktgröße untersucht. Nach Randomisierung erhielten 16 Patienten eine Nitroglycerin-Dauerinfusion über 48 h in einer Dosierung zwischen 0,6 und 6,0 mg/h, im Mittel 2,3 mg/h. 22 Patienten blieben ohne spezifische Therapie und dienten als Kontrollgruppe. Die Intervention erfolgte im Mittel 12±5 (±1 SD) Stunden nach Beginn der Schmerzsymptomatik und 8±5 h nach Beginn des CK-Anstieges. Die Infarktgröße wurde aus dem Aktivitäts-Zeitverlauf der Creatinkinase (CK) und des myokardialen Isoenzyms der CK (CK-MB) bestimmt. Mit einer Ausnahme wurden bei allen Patienten gleichzeitig die hämodynamischen Parameter (linksventrikulärer Füllungsdruck, arterieller Blutdruck, Herzminutenvolumen) gemessen. Das mittlere Infarktgewicht in der Kontrollgruppe betrug 51±30 g, in der Nitroglyceringruppe 48±33 g. Das aus der CK-MB errechnete Infarktgewicht betrug in der Kontrollgruppe 60±36 g (n=16) und im behandelten Kollektiv 52±41 g (n=11). Bei einem linksventrikulären Füllungsdruck (LVFP) unter 20 mm Hg betrug das Infarktgewicht in der Kontrollgruppe 43±30 g (n=12), in der Nitroglyceringruppe 41±32 g (n=11). Bei einem LVFP über 20 mm Hg betrug das Infarktgewicht in der Kontrollgruppe 61±29 g (n=10) gegenüber 64±32 g (n=5) in der mit Nitroglycerin behandelten Gruppe. Auch bei der aus den ersten 7 h vorausberechneten Infarktgröße ergab sich zur beobachteten Infarktgröße kein Unterschied. Trotz der bekannten günstigen Wirkung von Nitroglycerin auf Hämodynamik und myokardiale Ischämie nahm das Infarktgewicht nur geringfügig ab. Dabei ist jedoch zu berücksichtigen, daß der Interventionszeitpunkt relativ spät war (12 h). Bei Frühintervention scheint eine günstige Beeinflussung möglich zu sein.
    Notes: Summary In 38 patients with acute myocardial infarction the effect of nitroglycerin on infarct size was studied. Patients were randomized into two groups. 16 patients received continuous nitroglycerin infusions of 0.6 to 6.0 mg/h (mean 2.3 mg/h) over a 48 h period, 22 patients received no specific therapy and served as control. Nitroglycerin was given in the mean 12±5 (±1 SD) hours following onset of chest pain and 8±5 h after the increase of CK values. Infarct size was determined according to the time activity curve of creatine kinase (CK) and of its myocardial isoenzyme (CK-MB). In all but one patient hemodynamic parameters (left ventricular filling pressure, blood pressure, cardiac index) were measured. The mean infarct size was 51±30 CK-g-equiv. in control patients, and 48±33 g in nitroglycerin treated patients. Infarct size as calculated from CK-MB values was 60±36 g (n=16) in control, and 52±41 g (n=11) in treated patients. At left ventricular filling pressure values (LVFP) below 20 mm Hg infarct size amounted to 43±30 g (n=12) in control, and to 41±32 g (n=11) in the nitroglycerin group. At LVFP values above 20 mmHg infarct size was 61±29 g (n=10) in control as opposed to 64±32 g (n=5) in treated patients. There was no difference between infarct size as predicted during the first 7 h and the observed infarct size. - Despite the known beneficial effect of nitroglycerin on hemodynamics and on myocardial ischemia, infarct size seems not to be greatly reduced, however, intervention occurred fairly late (12 h). In early intervention beneficial effects seem likely.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    ISSN: 1432-1440
    Keywords: Hypertensive crisis ; Nitroglycerin ; Nifedipine ; Extensive hypertension
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary To determine whether nitroglycerin is as effective as nifedipine in lowering the blood pressure in severe hypertension and hypertensive crisis, two goups of 20 patients received in random sequence either 1.2 mg nitroglycerin sublingually or a 10-mg nifedipine capsule, which was chewed and swallowed. The blood pressure fell after 5 min in the nitroglycerin group from 211/122 mmHg to 171/95 mmHG and after nifedipine from 210/118 to 185/102 mmHg. The greater effect of nitroglycerine may result from faster absorption through the oral mucosa than through the small intestinal mucosa where nifedipine is primarily absorbed. After 15–20 min a satisfactory reduction in blood pressure was reached in both groups: 157/91 and 158/92 mmHg, respectively. After 30 min the heart rate in the nitroglycerin group had decreased from 83 to 80/min, but in the nifedipine group it had increased from 84 to 90/min. The reduction in blood pressure persisted up to 6 h. No significant differences in side effects were determined. Since a hypertensive crisis is usually accompanied by left ventricular failure, pulmonary edema, angina pectoris, or infarction, nitroglycerin has been definitively shown positively to influence these conditions, and preference should be given to nitroglycerin in the treatment of hypertensive crises.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    ISSN: 1432-1041
    Keywords: captopril ; congestive heart failure ; plasma aldosterone ; plasma prolactin ; metoclopramide ; dexamethasone suppression
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary After long-term captopril treatment, an inappropriate increase in aldosterone levels has been observed in hypertensive patients. It is not known, whether a similar change would occur in patients with severe congestive heart failure, and whether it is due to a decrease in endogenous dopaminergic inhibition of aldosterone secretion or to aldosterone stimulation by ACTH or an ACTH-related peptide. Therefore, the aldosterone and prolactin responses to metoclopramide have been studied in 10 patients with severe congestive heart failure (NYHA Class III or IV) after 6 months of captopril treatment, before and 11 h after pretreatment with dexamethasone. 7 placebo-treated patients served as double-blind controls. In captopril-treated patients, the supine aldosterone levels exceeded the normal range and were as high as in placebo-treated patients. The responsiveness of aldosterone and prolactin to metoclopramide was not influenced by captopril. Only in the placebo group were the aldosterone levels decreased by dexamethasone. Captopril increased plasma renin activity and serum potassium, and decreased supine epinephrine and norepinephrine and serum sodium. Thus, previous reports of inappropriately high aldosterone levels after long-term captopril treatment were confirmed in patients with severe congestive heart failure. It is concluded that increased aldosterone is due neither to a decrease in endogenous dopaminergic inhibition nor to dexamethasone-suppressible stimulation of aldosterone secretion.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Electronic Resource
    Electronic Resource
    Springer
    European journal of clinical pharmacology 38 (1990), S. S27 
    ISSN: 1432-1041
    Keywords: nitrate patches ; duration of action ; tolerance
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary Nitroglycerin patches deliver 0.003 mg nitroglycerin per minute through the skin. This small dose led to an antianginal effect in the short term and when applied with a nitrate pause at night also during sustained use. Minimal doses of i. v. nitroglycerin (0.025 mg) do have antianginal activity. This dose has no effect on pre- and afterload, but increases the diameter at the point of the stenosis. These findings are in accordance with newly won insights into the mode of action of nitrate in coronary heart disease. In the area of the stenosis EDRF cannot be produced by the intima because of damage resulting from arteriosclerotic plaques. EDRF is identical with NO. Thus, the administration of low doses of nitrates that act by means of the NO radical can increase the diameter in the stenosis, since the physiological dilator (EDRF) is no longer present. The increased flow caused by dilatation is the main factor in the antianginal activity of nitrates.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    ISSN: 1432-2013
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Die Wirkung des Adenosin und der Adeninnucleotide auf die Coronardurchblutung wurde am Hund und am isolierten Meerschweinchenherzen untersucht. Bei intracoronarer Dauerinfusion verhielten sich am Hund die Wirkungen äquimolarer Mengen von ASN und ATP wie 1:1. Am isolierten Herzen ergab sich die Relation ASN:AMP:ADP:ATP=1:0,76:1:1. Die Wirkung intracoronarer Dauerinfusionen von ASN und ATP am Hund wurde durch Persantin nicht beeinflußt. Am Meerschweinchenherzen konnte eine leichte Wirkungsverstärkung um den Faktor 1,7–1,9 beobachtet werden. Bei i.v. Dauerinfusion der Substanzen potenzierte Persantin am Hund die Wirkung von ASN und ATP in den von uns gewählten Zeitbereichen um den Faktor 32 und 52. Diese Potenzierung geschieht allein im Blut und ist durch die unter Persantin gehemmte Permeation des Adenosin durch die Erythrocytenmembran ausreichend erklärt. Am isolierten Herzen wurde die Wirkung von ASN, AMP und ATP durch Intensain weder im Sinne einer Wirkungsverstärkung noch im Sinne einer Wirkungsverlängerung beeinflußt. Die vorliegenden Befunde können die Auffassung, daß Adenosin bei der physiologischen Regulation der Coronardurchblutung als Überträgersubstanz eine Bedeutung hat, nicht stützen.
    Notes: Summary The effects on coronary flow of infusions of adenosine and adenosintriphosphate were studied in dogs and isolated guineapig hearts. Intracoronary infusions of equimolar doses of ASN and ATP in dogs produced equal effects. In isolated hearts the following relation of effects was found: ASN:AMP:ADP:ATP=1:0.76:1:1. The effects of intracoronary infusions of ASN and ATP in dogs were not influenced by persantin. In isolated guinea-pig hearts these substances showed slightly increased effects (1.7–1.9 times) during the action of persantin. The effects of intravenous infusions of ASN and ATP were potentiated by the factor 32 and 52 during the course of our experiments. This potentiation is caused solely by the blood and can be explained satisfactorily by the inhibited permeation of ASN through the membranes of erythrocytes as a result of the action of persantin. Intensain did not influence the effects of ASN, AMP and ATP in isolated hearts. The effects were neither potentiated nor prolonged. These findings do not support the hypothesis that adenosine has a function as a transmitter substance in the regulation of coronary blood flow.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 60 (1982), S. 77-85 
    ISSN: 1432-1440
    Keywords: Molsidomine ; Acute myocardial infarction ; Left- and right ventricular filling pressure ; ST-segment elevation ; Molsidomin ; Frischer Herzinfarkt ; Links- und rechts-ventrikulärer Füllungsdruck ; ST-Hebung
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Die hämodynamische Wirkung von Molsidomin und der Effekt auf die Myokardischämie wurde bei 48 Patienten mit frischem Herzinfarkt untersucht. In einer Dosierung von 8–12 mg in oraler und intravenöser Form führte Molsidomin zu einer signifikanten Senkung des linksventrikulären Füllungsdruckes. Bei Patienten mit einem Füllungsdruck unter 20 mm Hg fiel der diastolische Pulmonalarteriendruck bei 2×4 mg oral von 12,1 auf 8,8 mm Hg. Bei Patienten mit Linksinsuffizienz und linksventrikulärem Füllungsdruck über 20 mm Hg (Gruppe 2) wurde nach 12 mg intravenös eine Senkung des Füllungsdruckes von 23,8 auf 17,4 mm Hg erreicht. Es kam außerdem zu einer signifikanten Reduktion des rechten Vorhofdruckes in allen Dosisbereichen. Während bei nicht linksinsuffizienten Patienten (Gruppe 1) eine Reduktion des Herzminutenvolumens beobachtet wurde (5,7 auf 4,7 l/min) blieb das Herzminutenvolumen in Gruppe 2 unverändert. Die Herzfrequenz nahm in Gruppe 2 von 85 auf 81/min ab. Der arterielle Blutdruck reduzierte sich nur unter der höheren Dosierung um 10 mm Hg im Mittel, während in niedriger Dosierung der Blutdruck unverändert blieb. Der periphere Widerstand änderte sich dabei nicht. Die Vollwirkung war 30 min nach oraler Applikation erreicht. Drei Stunden später war die Wirkung auf die Hälfte reduziert. Nach 8 h war der Effekt nur noch minimal. Die Nebenwirkungsrate war gering, kurzfristige Kopfschmerzen traten nur bei 8% der Patienten auf. Beim intraindividuellen Vergleich mit 1,6 mg Nitroglycerin sublingual fand sich kein signifikanter Unterschied in der hämodynamischen Wirksamkeit (n=11). Molsidomin hat ähnlich wie Nitroglycerin einen günstigen Effekt auf die Hämodynamik und Myokardischämie. Es kommt primär zur Verminderung der Vorlast. Auch der mäßige Effekt auf die Nachbelastung mit geringer Senkung des arteriellen Druckes bei höheren Dosierungen kann als vorteilhaft angesehen werden.
    Notes: Summary The effect of molsidomine on hemodynamics and myocardial ischemia were studied in 48 patients with acute myocardial infarction. Between 8 and 12 mg of orally and intravenously administered molsidomine led to a significant reduction in left ventricular filling pressure. In response to 2×4 mg p.o., diastolic pulmonary arterial pressure fell from 12.1 to 8.8 mm Hg in patients with filling pressure below 20 mm Hg. Patients with left heart failure and left ventricular filling pressure above 20 mm Hg (Group 2) displayed a decline in filling pressure from 23.8 to 17.4 mm Hg following 12 mg i.v. In addition, right atrial pressure dropped significantly across the entire range of dosages. Although patients without left ventricular failure (Group 1) showed a decline in cardiac output (5.7 to 4.7 l/min), this parameter remained unchanged in Group 2. Heart rate in Group 2 fell from 85 to 81 per min. Arterial blood pressure was reduced by a mean of only 10 mm Hg at high dosages and remained unchanged at lower dosages. No change was observed in peripheral resistance. The maximum effect was seen 30 min after oral administration. Three hours later, the effect was reduced by half. Only minimal activity could be observed after 8 h. The incidence of side effects was low, with transient headaches occurring in 8% of the patients. An intraindividual comparison with 1.6 mg of sublingually administered nitroglycerin demonstrated no significant difference in hemodynamic effectiveness (n=11). Molsidomine, not unlike nitroglycerin, exerts a favorable effect on hemodynamics and myocardial ischemia. It acts primarily to reduce preload. The additional moderate effect on afterload with a slight decline in arterial pressure at high dosages may also be considered advantageous.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 61 (1983), S. 423-428 
    ISSN: 1432-1440
    Keywords: Nitrates ; Prognosis ; Coronary heart disease ; Dose of isosorbide dinitrate
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The daily dose of nitrates was determined in 293 patients who had undergone coronary angiography seven years earlier. A questionnaire was filled out by those still living; medical records and information provided by family physicians were used for those who had died during the intervening period. The dose could be ascertained in a total of 168 patients. Patients were divided into two groups: in group I were those with a daily isosorbide dinitrate dose of less than 40 mg (n=46), in group II those with a dose greater than 40 mg (n=72). 56 patients had died. Two-thirds of them had been on the low-dose regimen, whereas only one-third were in the high-dose group. The extent of ventricular impairment was comparable in both groups. Seven-year mortality in group I was 39% with a mean daily nitrate dose of 14 mg. In group II, however, only 26% died with a mean daily dose of 55 mg. The difference can already be seen during the first year. Age, extent of coronary sclerosis, degree of ventricular damage, and cardiac size were identical in both groups. Thus mortality rate in group II was reduced by 30–40%. A causal relation to the height of the nitrate dose should be considered.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    ISSN: 1432-1440
    Keywords: Isosorbide dinitrate ; Angina pectoris ; Sustained therapy ; Nitrate tolerance ; Exercise testing
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Ten patients with angiographically proven coronary heart disease, stable exercise-induced angina pectoris, and reproducible ST-segment depression were treated with isosorbide dinitrate (ISDN) tablets in daily doses of 240 mg (6×40 mg) and placebo (PL) for 28 days each on the basis of a randomized double-blind protocol with intraindividual cross-over. ISDN treatment resulted in a sustained reduction of anginal attacks with a weekly mean rate ranging from 1.4 (3rd week) to 3.9 (4th week) as compared to 10.2 (2nd week) to 11.7 (4th week) during placebo treatment (P〈0.001). Ischemic response during stress testing (sum of ST-segment depressions) was significantly improved during ISDN treatment as compared to placebo. Day 1: 56% (P〈0.01); day 7: 30% (P〈0.01); day 28: 49% (P〈0.001). Heart rate and arterial blood pressure in the upright position were different between ISDN and placebo on day 1 and day 7 of the treatment phases (P〈0.02), but not on day 28. Nitrate responsiveness with regard to blood pressure and heart rate was restored after a drug-free interval of 2 days. The plasma concentrations for ISDN and the mononitrate metabolites exhibited a constant ratio during the treatment period. Thus, therapy with 6 × 40 mg ISDN per day resulted in a sustained reduction of anginal attacks and preserved improvement of ischemic ST-segment depression during exercise in upright position.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 64 (1986), S. 884-896 
    ISSN: 1432-1440
    Keywords: Transluminale Angioplastie ; Dilatation ; renovaskuläre Hypertonie ; Nierenarterienstenose ; Nierenarterienverschluß ; Nierenarterienthrombose ; Nierenarterienembolie ; intraarterielle Thrombolyse ; Transluminal angioplasty ; Dilatation ; Renovascular hypertension ; Renal artery stenosis ; Renal artery occlusion ; Renal artery thrombosis ; Renal arterial embolism ; Intraarterial lysis
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary The development of percutaneous transluminal techniques has brought up new possibilities for causative treatment of renovascular hypertension. In renal artery stenosis transluminal angioplasty is meanwhile routinely applied; experience with angioplasty to date exceeds by far the number of 1000 published cases. Technical success is obtained in more than 90%. The clinical success in the therapy of reno-vascular hypertension is approximately 76% over all with nearly equal cure and improvement rates. In fibromuscular stenosis clinical success has been obtained in 95% with a cure rate of 56% and improval in 39%. The cure rate is particularly low in patients with atherosclerotic stenosis with 19%, however in 60% improvement has been obtained, resulting in clinical benefit in 79%. Results obtained by surgery seem to be superior to those of dilatation, especially with regard to cure rates. However, the differences are minor and are compensated by the evident advantages of transluminal dilatation, especially its easy application and lower risk. Thus, 8 years after its introduction in nephrology, transluminal dilatation is the therapy of choice in renal artery stenosis. Other nonoperative interventional techniques, including transcatheter aspiration and embolectomy, intraarterial thrombolysis, embolisation and modified angioplasty provided valuable alternatives to usual surgical therapy. However, experience with some of these procedures is still limited. The complication rate of transluminal angioplasty of 10–20%, necessitating surgery in nearly 5%, prohibits its uncritical use.
    Notes: Zusammenfassung Die Entwicklung percutaner transluminaler Kathetermethoden hat neue Möglichkeiten einer kausalen Behandlung der renovaskulären Hypertonie eröffnet. Bei Nierenarterienstenosen wird die transluminale Angioplastie mittlerweile in der Routinebehandlung angewandt; bis heute liegen Erfahrungsberichte von weit über 1000 behandelten Patienten vor. Die morphologisch-technische Erfolgsrate liegt über 90%, die klinische Erfolgsrate in der Behandlung der renovaskulären Hypertonie liegt in der Größenordnung von 76% mit nahezu gleichen Heilungs- und Besserungsraten. Bei Patienten mit fibromuskulärer Stenose ist das Verfahren in ca. 95% erfolgreich, mit einer Heilungsrate von ca. 56% und einer Besserung in 39%. Bei Patienten mit atherosklerotischer Stenose liegt die Heilungsrate mit ca. 19% besonders niedrig, jedoch wird in ca. 60% eine Verbesserung der Hypertonie erreicht, so daß sich eine Erfolgsrate von insgesamt 79% ergibt. Die Behandlungsergebnisse der chirurgischen Rekonstruktion scheinen denen der Dilatation etwas überlegen, insbesondere werden höhere Heilungsraten erzielt, wobei jedoch unterschiedliche Selektionsmodi zu berücksichtigen sind. Die unterschiedlichen Erfolgsraten sind jedoch für die klinische Praxis zu vernachlässigen und werden durch die evidenten Vorteile der Angioplastie mehr als ausgeglichen. 8 Jahre nach der Einführung in der Nephrologie stellt somit die transluminale Dilatation die Therapie der Wahl hämodynamisch relevanter Nierenarterienstenosen dar. Andere, nicht operative interventionelle Techniken, wie die Transkatheteraspiration und Transkatheterembolektomie, die intraarterielle Thrombolyse, die Embolisation und die modifizierte Angioplastie stellen wertvolle therapeutische Alternativen zu üblichen chirurgischen Verfahren dar. Die Erfahrungen auf dem Gebiet der Nephrologie sind bei einigen dieser Verfahren jedoch noch begrenzt. Eine kritische Abwägung von Nutzen und Risiko sowie eine präzise Indikationsstellung erscheinen unabdingbar, da bereits die Anwendung der transluminalen Angioplastie bei Nierenarterienstenosen in 10–20% zum Auftreten von Komplikationen, welche in fast 5% chirurgisch versorgt werden müssen, führt.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...